AU2002218862B2 - Method for purification of lactose - Google Patents

Method for purification of lactose Download PDF

Info

Publication number
AU2002218862B2
AU2002218862B2 AU2002218862A AU2002218862A AU2002218862B2 AU 2002218862 B2 AU2002218862 B2 AU 2002218862B2 AU 2002218862 A AU2002218862 A AU 2002218862A AU 2002218862 A AU2002218862 A AU 2002218862A AU 2002218862 B2 AU2002218862 B2 AU 2002218862B2
Authority
AU
Australia
Prior art keywords
lactose
solution
crystals
calcium
demineralisation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002218862A
Other versions
AU2002218862A1 (en
Inventor
Sean M. Dalziel
James Arthur Hourigan
Robert Leonard Johnson
Estelle Veronique Lifran
Robert Walter Sleigh
Robert John Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
University of Western Sydney
Dairy Australia Ltd
Original Assignee
Of Western Sydney, University of
Dairy Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2177A external-priority patent/AUPR217700A0/en
Application filed by Of Western Sydney, University of, Dairy Australia Ltd filed Critical Of Western Sydney, University of
Priority to AU2002218862A priority Critical patent/AU2002218862B2/en
Publication of AU2002218862A1 publication Critical patent/AU2002218862A1/en
Assigned to COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, DAIRY RESEARCH AND DEVELOPMENT CORPORATION, UNIVERSITY OF WESTERN SYDNEY reassignment COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION Request for Assignment Assignors: AUSTRALIAN FOOD INDUSTRY SCIENCE CENTRE, COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, DAIRY RESEARCH AND DEVELOPMENT CORPORATION, UNIVERSITY OF WESTERN SYDNEY
Assigned to UNIVERSITY OF WESTERN SYDNEY, DAIRY AUSTRALIA LIMITED, COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION reassignment UNIVERSITY OF WESTERN SYDNEY Request for Assignment Assignors: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION, DAIRY RESEARCH AND DEVELOPMENT CORPORATION, UNIVERSITY OF WESTERN SYDNEY
Application granted granted Critical
Publication of AU2002218862B2 publication Critical patent/AU2002218862B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/30Fuel from waste, e.g. synthetic alcohol or diesel
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02WCLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
    • Y02W30/00Technologies for solid waste management
    • Y02W30/40Bio-organic fraction processing; Production of fertilisers from the organic fraction of waste or refuse

Landscapes

  • Medicinal Preparation (AREA)

Description

WO 02/50089 PCT/AU01/01641 -1- METHOD FOR PURIFICATION OF LACTOSE TECHNICAL FIELD The present invention relates to improved methods of purification of sugars and in particular to a method of preparing lactose, lactose produced by the method and products comprising lactose produced by the method.
BACKGROUND
Industrial process waste streams such as dairy process streams are useful sources for the manufacture of sugars, in particular the manufacture of lactose. Whey, which is a watery liquid that separates from curd when milk is clotted, as in cheese making, contains valuable nutrients, including considerable amounts of lactose. Since lactose is a commercially important product particularly in the manufacture of infant milk-substitute formulas, confectionery, chocolate, baked goods, etc, several methods have been developed for its isolation from whey. Lactose also has important applications in the pharmaceutical industry particularly in tabletting and for dry powder inhalers.
To date, most methods for the production of refined edible or pharmaceutical grade lactose from whey involve more than one crystallisation step. Precipitation of lactose, however, is a relatively slow process and re-crystallisation increases both time and costs associated with production. Crude lactose a-monohydrate with an ash of 1% has recently been extracted from deproteinised whey using a water-ethanol one step crystallisation process (Yilmaz and Temiz, 1997, Milchwissenschaft 52 (11) p 62 9 6 3 1).
However, lactose obtained by such a method remains unsuitable for most food applications which require an ash content of (edible grade) or (refined edible) and for pharmaceutical applications which require an ash content of< 0.1%.
Singh et al (1991, J Food Sci 56 p.777-788) disclose demineralisation of whey permeate using ion exchange resins followed by alcoholic crystallisation directly from -2- Sthe resulting solution. Although pharmaceutical grade lactose can be obtained using this o method, the disadvantage of the method is that large columns of cation and anion Cc exchange resins are required and the lactose is crystallized at pH 2.5 in 80% ethanol with stirring for 3 h. Further, this method requires regeneration of columns and disposal of the ID 5 alkaline/salty regenerant, and involves an acid wash in which hydrochloric acid is 00 0 commonly used. It is well known that hydrochloric acid is corrosive to the stainless steel used in equipment, such as tanks, centrifuges, pumps, etc. in which these methods are N generally performed. Consequently, it would be desirable to have an alternative simple and economical process for the production of high purity lactose from a lower purity source.
It is an object of the present invention to provide a method of crystallisation of lactose and a product thereof which will overcome or substantially ameliorate at least some of the deficiencies of the prior art or provide a useful alternative.
The inclusion in this specification of references to prior art is not to be taken as an admission that the cited prior art, or any part thereof, comprises the common general knowledge of those skilled in the field of the invention.
SUMMARY OF THE INVENTION The present invention is based on the observation that a simple and economical process, which involves the removal of impurities such as proteins, mineral salts and riboflavin from a low purity lactose source by two demineralisation steps, can provide higher purity lactose.
According to a first aspect, the present invention provides a method of preparing high purity lactose from a lower purity lactose source including two demineralisation steps as follows:
I
-3a) primary demineralisation, and o b) secondary demineralisation of the resultant of step including the addition of z Cc alcohol in an amount, for a time, and at a temperature, sufficient to precipitate minerals.
Preferably, the resultant of step is crystallised by a further step Preferably, 00 00 the crystallisation is carried out by a single step procedure. Preferably, the crystallisation is carried out over a period of about 4 hours and more preferably over a period of about 2 hours.
Preferably, the primary demineralisation step includes treatment of the lower purity lactose source with divalent metal ions in an amount, for a time and at a temperature sufficient to remove certain mineral impurities before subjecting the lactose containing solution to alcohol treatment. However, it will be clear to the skilled addressee that the primary demineralisation step may be achieved by passage of the lower purity lactose source through a cation exchange resin (to remove divalent cations such as calcium and magnesium) and an anion exchange resin (to remove multivalent or divalent anions such as citrate or phosphate).
Preferably, the resultant of step is concentrated to 20% to 60% total solids before step Preferably, the divalent metal ion is calcium and more preferably the calcium is in the form of calcium chloride or calcium hydroxide (lime). However, it will be clear to the skilled addressee that other sources of divalent metal ions will also be useful e.g.
magnesium chloride or barium chloride. Preferably the divalent metal ion is present at a concentration of 0.014 to 0.025 M. The concentration will vary according to the level of precipitable divalent anions g. phosphate) present in the lactose source.
-4- O Preferably, the alcohol is ethanol. However, the skilled addressee will understand 0 that other alcohols may also be used in the invention such as methanol, isopropanol and propanol. Taking into account the boiling point and other relevant characteristics of these alcohols, the skilled addressee will be able to determine suitable and optimal conditions under which the method should be performed.
00 00 When the alcohol is ethanol, preferably, in step the ethanol is present at between 25% and 75% total liquid volume. Most preferably it is present at C1 approximately 60% total liquid volume.
Preferably, in step the temperature of the divalent metal ion-treated solution and the alcohol is between 40 0 C and 79°C. More preferably it is about 78 0
C.
Preferably, the step is carried out in alcohol and preferably the alcohol is present at between 25% to 75% total liquid volume. Preferably the crystals formed in step are washed with an alcoholic solution containing between 0% and 20% water.
Preferably, the lactose produced by the present invention has less than 0.3% ash.
Most preferably it is pharmaceutical grade lactose with less than 0.1% ash.
Preferably, if clarified whey (screened to remove cheese particles and centrifuged to remove fat) is used as a lactose source, the divalent metal ion treatment step is preceded by an ultrafiltration step to obtain whey permeate. The divalent metal ion treated solution is optionally treated with absorbents such as charcoal, and then advantageously concentrated by nanofiltration and evaporation prior to treating with alcohol to precipitate the residual minerals.
Lactose crystals obtained by the method of the invention are optionally recovered by centrifugation, washed and dried.
According to a second aspect, the present invention provides a method for o preparation of lactose crystals of pharmaceutical grade from clarified whey solution including the steps of: ultrafiltration of the clarified whey solution to obtain whey permeate;
OD
00 00 5 primary demineralisation of the solution from step by treatment with 0.014 CI to 0.025 M calcium chloride and/or calcium hydroxide; filtration or centrifugation of the solution from step and, optionally, treatment of the solution with charcoal; concentration of the solution from step to 20% to 60% total solids, preferably by nanofiltration, evaporation or reverse osmosis; secondary demineralisation by addition of ethanol to the solution from step (d) to a final concentration of about filtration or centrifugation of the solution from step crystallisation of lactose from the solution from step(f); centrifugation of the solution from step and removal of lactose crystals; and washing lactose crystals obtained in step with an alcoholic solution containing between 0% and 20% water and drying the crystals.
According to a third aspect, the present invention provides an improved method for the preparation of lactose crystals of at least food grade standard from a lower purity lactose source, the improvement including the steps of: -0o- Sa) treating a solution containing lactose with divalent metal ions in an amount, and 0 for a time, sufficient to remove a proportion of minerals contained in the z Ssolution; and b) treating the divalent metal ion-treated solution with alcohol in an amount, and for a time, sufficient to remove residual minerals from the solution.
00 00 0 According to a fourth aspect, the present invention provides lactose produced by a method according to any one of the first to third aspects.
N According to a fifth aspect, the present invention provides lactose comprising rosette-shaped crystals.
Preferably, the lactose is of at least food grade standard. Most preferably the lactose is pharmaceutical grade lactose. Preferably, the lactose has a bulk density of 0.40 to 0.70 g/ml.
According to a sixth aspect, the present invention provides a pharmaceutical or veterinary preparation comprising lactose according to the fourth or fifth aspects, preferably wherein the preparation is in the form of a powder, tablet, capsule or caplet.
In one or more preferred embodiments, the present invention provides a product comprising lactose according to the fourth or fifth aspects.
Preferably, the product is a food product. In one embodiment, the product is an infant formula or milk substitute formula. However, it will be clear to the skilled addressee that the product may be any product in which the lactose obtained by the method of the present invention would be useful and the skilled addressee will be aware of such products. For example, in addition to the products indicated above, the product may also be an agricultural product.
Preferably the free-flowing properties of the lactose crystals obtainable by the present method are particularly useful in tablet products and agricultural products in the form of tablets are specifically contemplated e.g. fertilisers, insecticides, fungicides and o the like.
z SIt will be clear to the skilled addressee that by-products of the invention are also contemplated.
According to a seventh aspect, the present invention provides a by-product of the 00 oO 0 method of any one of the first to third aspects wherein the product comprises 403 23g/ 100Og citric acid, 44 17g/1 OOg sodium, 186 48g/1 OOg potassium and 353 109g/100g calcium.
Preferably, the by-product is a calcium-rich mineral fraction.
In one or more preferred embodiments, the present invention provides a food product including a by-product according to the seventh aspect, preferably wherein the food product is a sports, diet and/or dairy food.
In one or more preferred embodiments, the present invention provides a drink product including a by-product according to the seventh aspect, preferably wherein the drink product is a sports, diet and/or dairy drink.
In the context of the present invention, the term "demineralisation" means precipitation of impurities followed by removal of the impurities.
In the context of the present invention, the term "lower purity lactose source" encompasses sources of lactose which range from very crude sources such as products of the dairy industry e.g. whey, to sources which have previously been purified by other methods including, for example, refined food grade lactose and the like. However, it does not include a source in which the lactose is solely pharmaceutical grade lactose.
In the context of the present invention, the term "high purity lactose "refers to lactose having less than 1% ash such as, for example, food grade lactose (currently 0.3% ash), refined food grade lactose (currently 0.2% ash) and pharmaceutical grade 7a- -i lactose (currently 0. 1% ash).
o Unless the context clearly requires otherwise, throughout the description and the Cc claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the 5 sense of"including, but not limited to".
00 00 It will be understood that the principles described above may also be applied to c purification of other sugars, for example sucrose, glucose, fructose and fruit sugars 7 WO 02/50089 PCT/AU01/01641 -8- BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Micrograph of crystals of 100 mesh Wyndale a lactose monohydrate from The Lactose Company of New Zealand, Havera, New Zealand; Figure 2 Micrograph of Pharmatose: roller dried anhydrous lactose from DMV International, Veghel, The Netherlands; Figure 3 Micrograph of Wyndale Supertab: spray dried lactose, a mix of a lactose monohydrate and amorphous lactose from The Lactose Company of New Zealand, Havera, New Zealand; and Figure 4 Micrograph of lactose crystals of the present invention.
DESCRIPTION OF THE INVENTION A preferred embodiment of the invention will now be described, by way of example only. The method described is referred to hereinafter as the "accelerated alcoholic crystallisation" (AAC) method.
This embodiment involves the addition of calcium to the permeate from the ultrafiltration of whey to remove minerals. This addition is followed by nanofiltration and evaporation (concentration) of the calcium treated whey permeate. This addition is then followed by ethanol treatment. The minerals precipitated by the addition of ethanol are removed and the lactose crystallised, the crystals washed and dried. The steps lead to four different fractions. The main product recovered is highly pure lactose. Also recovered are a mineral fraction from the calcium treatment step, a mineral fraction from the alcoholic demineralisation step and molasses from the mother liquor. The ethanol left in the alcoholic mineral precipitate and the mother liquor can be recycled if recovered by distillation.
WO 02/50089 PCT/AU01/01641 -9- The different steps of the process are shown on the AAC process flow chart (Scheme The calcium-treatment: adjusting the pH to 7 by addition of calcium chloride and sodium hydroxide or calcium hydroxide and then centrifuging, enables an efficient demineralisation of the whey permeate by producing a mineral fraction rich in calcium, phosphate and citrate. This fraction can be roller dried into a white powder.
The calcium-treatment step can also be substituted by the use of cation and anion resins.
The whey permeate is then concentrated in two steps by nanofiltration and evaporation up to 50% total solids.
With the addition of alcohol to the lactose solution, residual minerals precipitate and are removed from solution by centrifugation or filtration, which is followed by crystallisation, washing and drying of the lactose crystals.
Example 1 Primary demineralisation The calcium-treatment step is the first part of the AAC process, which comprises unit steps. The raw material for the AAC process can be whey coming from the manufacture of cheese. The chemical composition of cheese whey is described in table 1 with data from both the literature and experiments.
When cheese whey is used, it is first seived to remove fines, centrifuged to remove fat, pasteurized and then ultrafiltered producing 2 streams: ultrafiltration (UF) retentate and whey permeate. The UF retentate has preferably 12% solids and 5.2% lactose. The ash of this UF retentate is 0.99% 0.13. The whey permeate chemical composition is presented in table 2.
The next step is called primary demineralisation. It is the first critical step of the process. The whey permeate is neutralised to pH 7 by addition of Calcium Chloride and Sodium Hydroxide or Calcium Hydroxide. The whey is then heated to 60 0 C and kept at WO 02/50089 PCT/AU01/01641 PROCESS FLOW CHART fltrafiltration 4 Whey permeate cF adum treatment UF Retentate I Cenraso rilrtol -40 Mineral Precipitate Drying -0 Calcium-rich Mineral Fraction Nanofiltration] Salty Water (Permeate) Nanofiltered whey (retentate) SEvapation 0. Condensate Water Demisaon4eaMlr I italion 1 Denineralisation Mineral Fraction Drying Mineral powder Crystallisa;on ICentrifugaboncrystals recovery -p Mother Liquor Drying -0 Dry Molasses SCrystas whng Crystals drying "Highly pure" Lactose Washing Solution WO 02/50089 PCT/AU01/01641 11 this temperature for 15 minutes during which time a precipitate is formed and is subsequently removed by centrifugation or filtration.
The chemical compositions of both the calcium-treated whey permeate and the precipitate (called calcium rich mineral fraction) are described in table 3. The calciumtreated whey permeate is either pumped through a charcoal column and/or cooled to around 20°C before being nanofiltered. The temperature of the lactose solution pumped to the nanofiltration unit depends upon the characteristics of the membranes used in the nanofilter. Usually as the temperature increases the proportion of lactose permeating through the nanofilter membrane increases. The lower temperature 20 0 C) is thus used to minimise the loss of lactose into the nanofiltration permeate. The charcoal column treatment is an optional step that can be done either before or after the nanofiltration.
WO 02/50089 PCT/AU01/01641 -12- Table 3: Chemical composition of calcium-treated whey permeate and calcium rich mineral fraction.
Component Ca-treated whey permeate Ca-rich mineral fraction g/100g Whey g/100g Precipitate Dry matter 5.3 0.6 25 2.4 Ash 0.91 0.2 9.5 0.73 Lactose 4.27 1.2 6.75 1.78 mg/100g Whey mg/100g Precipitate Citric acid 115+/-16 1794+/-163 Sodium 44 8.7 108 Potassium 147 8.2 192 Calcium 107 50 4002 449 Magnesium 6.6 0.9 80 18 Phosphorus 1.5 1966+/- 147 Sulphur 6.6 2.8 24 13 The calcium-rich mineral fraction can be dried roller drying) to give a white to off-white powder. This powder should be useable in a number of calcium and mineral supplemented products such as sports drinks, dairy drinks, sports and diet food, chocolate and so on. This powder has to be considered not so much as a by-product but rather as a value-added product with a "natural" marketing advantage.
The nanofiltration of the calcium-treated whey permeate produces two streams of liquid products: some salty water as the permeate; and, the concentrated whey as the nanofilter retentate. The chemical composition of the nanofilter retentate is presented in table 4.
WO 02/50089 PCT/AU01/01641 -13- Table 4: Chemical composition ofnanofilter retentate.
Component Nanofilter Retentate g/100g Retentate Dry matter 19.2 1.9 Ash 0.43 Lactose 15.4 mg/100g Retentate Citric acid 403 23 Sodium 17 Potassium 186 48 Calcium 353 109 Magnesium 25 3.4 Phosphorus 35 4.4 Sulphur 15+/-3 The nanofiltration step is used to not only concentrate the calcium-treated whey, but also to effectively reduce, when compared with the effect of direct evaporation, the potassium and sodium concentrations in the nanofilter retentate. The calcium-treated whey is concentrated to 20°Brix which is higher than that obtained in most other industrial scale nanofiltration processes. This concentration is readily achievable because of the smaller osmotic pressure across the nanofilter membrane due to low divalent salt concentrations in the calcium-treated whey permeate. However, the permeate is not concentrated above 20°Brix because the flux across the membrane drops rapidly at 20°Brix, making further concentration uneconomic compared to evaporation.
WO 02/50089 PCT/AU01/01641 -14- Also the constant proportional percentage of lactose lost through the membranes used is minimised by these process conditions: 20 Bar, 20 0 C maximum, 20°Brix maximum.
The last step of the calcium-treatment is to further concentrate the nanofilter retentate. A multi-effect evaporator is usually used to take the total solids from to between 400 and 50°Brix. The chemical composition of the concentrated nanofilter retentate (CNR) is shown on Table Table 5: Chemical composition of concentrated nanofilter retentate (CNR).
Component Concentrated nanofilter retentate g/lOOg retentate Dry matter 41 4 Ash 3.89 0.9 Lactose 38 0.33 mg/100g retentate Citric acid 787 18 Sodium 94.3 38 Potassium 408 Calcium 656 23 Magnesium 55 Phosphorus 70 Sulphur 31 WO 02/50089 PCT/AU01/01641 Example 2 Alcohol addition step The AAC process includes an alcohol treatment of the concentrated nanofilter retentate (CNR) as a further demineralisation step, followed by filtration, crystallisation, washing and drying of the crystals.
As an example, the basic unit operations for the alcohol addition stage of the AAC process, include: Pumping 40Kg of the CNR at a flow rate equivalent to 4Kg/min from a storage tank, through a heat exchanger to bring the CNR from 45 0 C to 780C, and into the first stirred tank called the "demineraliser".
Pumping 30L 100% ethanol (volume of ethanol to add is 60% of total liquid [water ethanol]) at a flow rate equivalent to 3L/min from a storage tank, through a heat exchanger to bring the ethanol from room temperature to 780C, and into the demineraliser.
Demineralising the alcoholic CNR by leaving it under reflux at 780C and low stirring for one to 15 minutes. A condenser fitted on the lid of the demineraliser tank, condenses the alcoholic vapours which are returned to the demineraliser tank.
Filtering the alcoholic CNR solution after step by pumping the mixture at an average flow rate of 2L/min, through a 1utm filter at 780C. This filtration step removes the precipitated solids from the alcoholic CNR liquid phase.
Steps and are called the "demineralisation step". It produces a precipitate recovered by filtration called "alcoholic demineralisation mineral fraction".
The alcoholic demineralised CNR is then ready for the crystallisation step. Table 6 describes the chemical composition of the alcoholic demineralisation mineral fraction.
WO 02/50089 PCT/AU01/01641 -16- Crystallising lactose by cooling the solution in a second stirred tank called the "crystalliser" over 2 hours. Seeding the erystalliser (adding a small amount of lactose crystals of a known crystal size) is also necessary at this stage.
Separating the crop of lactose crystals from the mother liquor by centrifugation.
Gravity or a pump can be used to feed the mixture containing the lactose crystals into the centrifuge. The crystals are retained in the centrifuge while the mother liquor spun-off is pumped into a waste drum. The ethanol left in the mother liquor can be recovered by distillation and recycled. The solids left in the mother liquor can be dried into a powder called "dry molasses". The chemical composition of the dried mother liquor is presented in table 7.
Washing the crop of lactose crystals. The washing solution, consisting of between and 100% v/v ethanol with the remainder water, is heated to 70-75C by pumping through the ethanol heat exchanger. The volume of washing solution used is proportional to the amount of solids present in the concentrated whey at the start of the AAC process. From two to six litres of washing solution should be used per Kg of solids present. The washing solution can be recycled by distillation. Its chemical composition is described in table 7. Highly pure lactose crystals were also produced with a washing solution that had its pH adjusted to 2 with hydrochloric acid.
The combination of the four steps described: calcium-treatment, ethanolic demineralisation, crystallisation and crystal washing, results in a crop of lactose crystals of very high purity which may be suitable for use in the pharmaceutical industry..
The process lactose specifications are described in table 8.
Drying the crystals under mild conditions: preferably at or below 60'C in a fluidised bed dryer.
WO 02/50089 WO 02/50089PC T/AUO 10 1641 17- Table 6: Chemical composition of the demnineralisation mineral fraction.
Component Alcoholic Demineralisation mineral fraction g/lO0g Precipitate Dry matter 40+/-2 Ash 15+/-3 Lactose 16 Citric acid 4.9+1- 1.1 Sodium 0.25 0.02 Potassium 0.92 0.08 Calcium 7.6+/-l1 Magnesium 0.24 0.01 Phosphorus 0.37 0.05 Sulphur 0.25 0.06 WO 02/50089 PCT/AU01/01641 -18- Table 7: Chemical composition of the dried mother liquor and washing solution.
Component Dried Mother liquor Washing Solution g/100g Molasses g/100g Solution Dry matter 11+/-2.5 1.11 Ash 2.34 0.5 0.24 Lactose 1 0.572 mg/100g Molasses mg/100g Solution Citric acid 459 30 60 Sodium 92 30 Potassium 340 54 37 Calcium 454 50 29 Magnesium 50 3 4.4 Phosphorus 47 20 Sulphur 30 10 2.2 WO 02/50089 PCT/AU01/01641 -19- Table 8: AAC lactose specifications.
Component AAC Lactose Lactose 99.8% min.
Water Sulphated Ash 0.3% Loss on drying 0.047% Specific rotation 55.90 Heavy metals Arsenic <0.25 mg/Kg Acidity ml 0.1N NaOH/6g 0.15ml/6g Protein and light-absorbing 210-220 nm: 0.14 max.
impurities absorbance 270-400 nm: 0.07 max.
Solution appearance clear, colourless Sediment absent/100g Total bacterial count 100/g max Yeasts and moulds 50/g max Coliforms Negative/g Escherichia Coli Negative/1Og Salmonella species Negative/100 g Example 3 Properties of Lactose The pharmaceutical applications study first involved the evaluation of the physico-chemical properties of 4 pharmaceutical grade lactose powders: The AAC lactose; and WO 02/50089 PCT/AU01/01641 3 other commercially available products: Pharmatose, DMV, roller dried, high beta content, anhydrous lactose.
USP-100 mesh alpha lactose monohydrate from Wyndale New Zealand.
Supertab, Wyndale New Zealand, spray dried, mix of alpha lactose monohydrate and amorphous lactose.
While there are records in the literature of extensive testing of many of the commercially-available pharmaceutical grade lactoses, it was important to validate the tests on the AAC lactose by performing the same tests at the same time on the commercial products.
The physico-chemical properties that were studied were: The particle shape of the crystals by scanning electron microscopy.
The particle size by laser diffraction (Malvem Particle Sizer).
The bulk density (mass of known volume of particles) and tap density (mass of a known volume of compacted particles).
The moisture content.
The flow properties or flowability. The flowability is the time it takes for a certain amount of lactose powder to flow through a tube of known diameter. It is expressed in grams per second. Tables 9 and 10 present the results of the 4 lactose powders physico-chemical properties study.
The usual shape of crystalline lactose is the one presented in Figure 1, the micrograph of the USP-100 mesh Wyndale powder.
Figures 2 and 3 respectively present micrographs of Supertab spray dried lactose that has a spherical shape and Pharmatose roller dried lactose that has very irregular shape.
WO 02/50089 PCT/AU01/01641 -21- The AAC crystals have a shape which we have called "rosette" (Figure One crystal is made of a number of small microcrystals aggregated together. The AAC crystals can have a higher surface to mass ratio than commercially available lactose.
This is also reflected by their higher bulk density (see table The method used to study the particle size was the Malvem Particle Sizer. It works on the principle of laser diffraction. The light source is a Helium-Neon laser.
Particles are introduced into the beam; the light is scattered and then collected by a receiver lens. A detector operates in the form of a series of 31 concentric annular rings.
Data is collected into a computer for further processing and printing.
Table 9: Particle size distribution.
Particle Size Distribution (microns) Lactose Powder 10% 50% 90% Mean Particle under under under Size AAC 1 pharmaceutical grade 68 162 261 163 AAC 2 refined edible grade 40 119 189 116 AAC 3 refined edible grade 46 133 262 151 Pharmatose DMV 22 150 250 150 USP-100 mesh Wyndale 37 112 250 100 Supertab Wyndale 47 145 250 150 WO 02/50089 PCT/AU01/01641 -22- Table 10: AAC lactose tap density, bulk density, moisture content and flowability.
Comparison with some commercially available lactose powders.
Material Tap density Bulk density Moisture Flowability g/cm 3 g/ml g/10Og g/s AAC 1 0.56 0.53 5.400 4.6 AAC 2 0.54 0.43 5.020 3.7 AAC 3 0.54 0.45 5.335 4 Pharmatose 0.65 0.220 0 USP-100 mesh 0.96 0.82 4.730 5.2 Supertab 0.77 0.64 5.180 4 Bulk density measurements made with a 100 0.375 ml glass cylinder; means of 6 measurements.
Tap density measurements made with a 477.2 cm 3 cylinder; means of 6 measurements.
Moisture content: used an IR moisture determination balance MA 30, 140 0 C, 7 min; means of 2 measurements.
Flowability measurements made using a static funnel, a tube a known diameter (8mm) and a balance; means of 5 measurements.
Example 4 Tabletting trials There are 3 different ways to make tablets: dry granulation, wet granulation and direct compression. In the granulation processes, the drug, the excipient and other additives are mixed and then granulated. Granulation improves the flow properties. If the flow properties are poor, this will lead to variations in the fill of the tablet die and will result in weight variation and therefore in dose variation. Once the mix is free WO 02/50089 PCT/AU01/01641 -23flowing, it is compressed in a tabletting machine. Some powder is pushed into the tablet die, then compressed by a puncher and finally the tablet ejected from the die.
The direct compression technique was developed in the sixties when spray dried lactose appeared on the market. Spray dried lactose had relatively good flow properties and it also had excellent binding properties hence it could be compressed without granulation.
Avoiding the granulation steps saves a lot of time but on the other hand, the quality of the excipient has to be higher with good flow and good binding properties and also good storage stability. The excipient should also allow the drug to be made available at the right time. The mixing step is critical in direct compression because this is the only way to make sure the drug dose will be the same for all the tablets. For the 3 lactose powders we had to compare, we applied the same conditions of formulation, mixing, processing and testing. The tabletting machine used was a Manesty type F8.
Once the tablets were made, 5 tests were performed to assess the tablet quality.
The first test was the number of tablets produced per kilo of lactose and the yield.
AAC lactose gave 1152 tablets with a yield of 60%. This means the production was of the tablets we could theoretically have made. Pharmatose gave 1038 tablets with a yield of 54%. Supertab gave 891 tablets with a yield of 46%. The better result of AAC lactose comes from the fact it has bigger crystals and less fines. Less lactose is lost either as dust or as powder escaping the machine die.
The second test was hardness. The number indicates if the tablet is soft or strong and reflects the binding properties of the excipient. A good hardness is usually around 5-6 KPa. AAC lactose was 5.7 KPa, Pharmatose was 5.7 and Supertab 4.7 KPa. There was not much difference for this parameter. The test was performed with a Schleuniger tester.
WO 02/50089 PCT/AU01/01641 -24- The friability test indicates the ability to withstand aggressive handling. The tablets are going to be carried along the processing line to be packaged then transported and stored.
Friability gives the percentage of material lost during handling. The smaller the value the better. AAC lactose performed well with only 0.43% friability against 0.51% for Pharmatose and 1.95% for Supertab. The test was performed on a Erweka-Apparatebau machine.
Disintegration time is the time it takes to a tablet to disintegrate under mechanical and chemical actions. This test shows how long the tablet takes to break up (but not to dissolve as opposed to the solubility test) and demonstrate the ability of the tablet to release the drug quickly. Disintegration time depends on the excipient properties. AAC lactose tablets disintegrate the fastest. The drug will be able to dissolve in the stomach media as soon as the tablets are disintegrated and release the drug.
The dissolution test shows how fast the drug will dissolve in the stomach to be available for absorption. According to the British Pharmacopoeia, 70% of the drug has to dissolve in 0.1M HC1 at 37 0 C (to mimic the stomach conditions) within 45 minutes.
The drug we used in the trials was caffeine as it was readily available to us. 94.5% of the caffeine was dissolved after 45 minutes in the AAC tablets against only 73% for Pharmatose and 77.5% for Supertab.
These tabletting trials showed that AAC lactose could be an excellent excipient in direct compression but its properties make it also useful in a wider range of applications. AAC lactose has a "rosette" particle shape, ideal particle size distribution without hammer milling, excellent flow properties, good compressibility, low friability, fast disintegration and high drug release.
WO 02/50089 PCT/AUO1I/01641 Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms.

Claims (17)

  1. 2. A method according to claim 1 wherein the resultant of step is crystallised by a further step preferably wherein step is a single step procedure.
  2. 3. A method according to claim 1 or claim 2 wherein the primary demineralisation step includes treatment of the lower purity lactose source with divalent metal ions in an amount, for a time and at a temperature sufficient to remove certain mineral impurities before subjecting the lactose-containing solution to alcohol treatment.
  3. 4. A method according to any one of claims 1 to 3 wherein the primary demineralisation step is achieved by passage of the lower purity lactose source through a cation exchange resin and/or an anion exchange resin. A method according to any one of claims 1 to 4 wherein the resultant of step is concentrated to 20% to 60% total solids before step
  4. 6. A method according to any one of claims 1 to 5 wherein the divalent metal ion is calcium, preferably from calcium chloride or calcium hydroxide; magnesium, preferably from magnesium chloride; or barium, preferably from barium chloride.
  5. 7. A method according to any one of claims 1 to 6 wherein the divalent metal ion is present at a concentration of 0.014 to 0.025 M.
  6. 8. A method according to any one of claims 1 to 7 wherein the alcohol is ethanol, methanol, isopropanol or propanol. -27-
  7. 9. A method according to any one of claims 1 to 8 wherein in step the alcohol is ethanol, and is present at between 25% and 75% total liquid volume, preferably wherein Z the ethanol is present at approximately 60% total liquid volume. A method according to any one of claims 1 to 9 wherein in step the temperature of the divalent metal ion-treated solution and the alcohol is between 40 0 C and 79 C, -0 preferably wherein the temperature is about 78 0 C. 00 0
  8. 11. A method according to any one of claims 1 to 10 wherein the high purity lactose has less than 0.3% ash, preferably wherein the high purity lactose has less than 0.1% ash.
  9. 12. A method for preparation of lactose crystals of pharmaceutical grade from clarified whey solution including the steps of: ultrafiltration of the clarified whey solution to obtain whey permeate; primary demineralisation of the solution from step by treatment with 0.014 to 0.025 M calcium chloride and/or calcium hydroxide; filtration or centrifugation of the solution from step and, optionally, treatment of the solution with charcoal; concentration of the solution from step to 20% to 60% total solids, preferably by nanofiltration and evaporation, or reverse osmosis; secondary demineralisation by addition of ethanol to the solution from step (d) to a final concentration of about filtration or centrifugation of the solution from step crystallisation of lactose from the solution from step centrifugation of the solution from step and removal of lactose crystals; and washing lactose crystals obtained in step with an alcoholic solution containing between 0% and 20% water and drying the crystals. -28-
  10. 13. An improved method for the preparation of lactose crystals of at least food grade standard from a lower purity lactose source, the improvement including the steps of: z Cc treating a solution containing lactose with divalent metal ions in an amount, and for a time, sufficient to remove a proportion of minerals contained in the solution; and O0 00 treating the divalent metal ion-treated solution with alcohol in an amount, and 0 for a time, sufficient to remove residual minerals from the solution.
  11. 14. Lactose produced by a method according to any one of claims 1 to 13. Lactose comprising rosette-shaped crystals.
  12. 16. Lactose according to claim 14 or claim 15 wherein the lactose has a bulk density of 0.40 to 0.70 g/ml.
  13. 17. Lactose according to any one of claims 14 to 16 wherein the lactose has a tapped bulk density of 0.56g/ml or less, preferably wherein the lactose has a tapped bulk density of about 0.54 to 0.56g/ml.
  14. 18. Lactose according to any one of claims 14 to 17 wherein the lactose is of at least food grade standard, preferably wherein the lactose is pharmaceutical grade lactose.
  15. 19. A pharmaceutical or veterinary preparation comprising lactose according to any one of claims 14 to 18, preferably wherein the preparation is in the form of a powder, tablet, capsule or caplet.
  16. 20. A by-product of the method of any one of claims 1 to 13 wherein the product comprises 403 23g/1 OOg citric acid, 44 17g/l OOg sodium, 186 48g/1 OOg potassium and 353 109g/100g calcium.
  17. 21. A method of preparing high purity lactose from a lower purity lactose solution; a method for producing lactose crystals of pharmaceutical grade from clarified whey solution; an improved method for the preparation of lactose crystals of at least food grade standard from a lower purity lactose source; lactose produced by a method according to any one of claims 1 to 20; lactose comprising rosette-shaped crystals; a -29- pharmaceutical or veterinary preparation comprising lactose according to any one of claims 14 to 18; or a by-product of the method of any one of claims 1 to 20 lactose, Z substantially as herein described with reference to any one of the accompanying examples but excluding comparative examples. IND 00 00 0", t(,
AU2002218862A 2000-12-19 2001-12-19 Method for purification of lactose Ceased AU2002218862B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002218862A AU2002218862B2 (en) 2000-12-19 2001-12-19 Method for purification of lactose

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR2177 2000-12-19
AUPR2177A AUPR217700A0 (en) 2000-12-19 2000-12-19 Methods for purification of lactose
PCT/AU2001/001641 WO2002050089A1 (en) 2000-12-19 2001-12-19 Method for purification of lactose
AU2002218862A AU2002218862B2 (en) 2000-12-19 2001-12-19 Method for purification of lactose

Publications (2)

Publication Number Publication Date
AU2002218862A1 AU2002218862A1 (en) 2002-09-05
AU2002218862B2 true AU2002218862B2 (en) 2008-05-22

Family

ID=39432798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218862A Ceased AU2002218862B2 (en) 2000-12-19 2001-12-19 Method for purification of lactose

Country Status (1)

Country Link
AU (1) AU2002218862B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971191A4 (en) * 2013-03-15 2016-12-07 Paul Stephenson Lactose recovery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Singh R K et al, J. Food Science, 1991, 56(3), pp777-771 and 778. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971191A4 (en) * 2013-03-15 2016-12-07 Paul Stephenson Lactose recovery

Similar Documents

Publication Publication Date Title
US20110034685A1 (en) Method for Purification of Lactose
US20080299287A1 (en) Process For The Recovery Of A Brown Food-Grade Sugar Product From A Sugar Beet Solution
US8394443B2 (en) Modified whey powder and process for producing the same
JPS5912278B2 (en) Method for producing nutritional sugar from sweet potato juice
WO2003092730A1 (en) Hydroxycitric acid salt composition and method of making
Hourigan et al. Lactose: chemistry, processing, and utilization
JP2022166190A (en) Method for producing rebaudioside d-containing crystallized product and rebaudioside d-containing crystallized product
AU2002218862B2 (en) Method for purification of lactose
Durham Modern approaches to lactose production
JP4530342B2 (en) Method and apparatus for producing honey-containing sugar
MX2012004278A (en) Methionine-rich composition for feeding animals.
US5454875A (en) Softening and purification of molasses or syrup
JP2006020521A5 (en)
Singh et al. α‐Lactose monohydrate from ultrafiltered whey permeate in one‐step crystallization using ethanol‐water mixtures
JP2020509073A (en) Process for crystallizing 2&#39;-fucosyllactose and related compositions
WO2006125286A1 (en) Process for the production of pyrogen-free anhydrous crystalline dextrose of high purity from sucrose
EP1498498B1 (en) Whey powders of improved taste
US20090155391A1 (en) Hydroxycitric acid salt composition and method of use for reducing body weight
JP3589357B2 (en) Method for preparing crystalline lactulose from commercial syrup
JP2000232900A (en) Production of dehydrated crystalline glucose
EP4052772A1 (en) Method for manufacturing revaudioside-d-containing crystallized product, and revaudioside-d-containing crystallized product
JP2978609B2 (en) Method for producing salty seasonings containing potassium
JPH04341200A (en) Powdery molasses-containing sugar containing raffinose, its production and drying apparatus therefor
DE804092C (en) Process for the manufacture of a milk sugar product
RU2203959C2 (en) Lactulose preparation method and installation for implementation thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DAIRY RESEARCH AND DEVELOPMENT CORPORATION; UNIVER

Free format text: FORMER APPLICANT(S): DAIRY RESEARCH AND DEVELOPMENT CORPORATION; COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION; UNIVERSITY OF WESTERN SYDNEY; AUSTRALIAN FOOD INDUSTRY SCIENCE CENTRE

PC1 Assignment before grant (sect. 113)

Owner name: UNIVERSITY OF WESTERN SYDNEY; COMMONWEALTH SCIENTI

Free format text: FORMER APPLICANT(S): UNIVERSITY OF WESTERN SYDNEY; COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION; DAIRY RESEARCH AND DEVELOPMENT CORPORATION

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired